Showing 61-70 of 5788 results for "".
Treatment of Basal Cell Carcinomas in Elderly Patients
https://practicaldermatology.com/topics/general-topics/treatment-of-basal-cell-carcinomas-in-elderly-patients/21748/BCCs are increasingly prevalent in older patients. While surgery remains the gold standard of treatment, existing and emerging therapies may enhance outcomes.SCALE 2019: Meeting Highlights from Music City
https://practicaldermatology.com/topics/practice-management/scale-2019-meeting-highlights-from-music-city/19619/With an emphasis on both medical and cosmetic dermatology as well as practice management, Music City Scale or the Symposium for Cosmetic Advances and Laser Education has something for everyone, organizers says. Co-chairs Michael Gold, MD and Brian Biesman, MD are joined by several presenters to discBimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuAK Therapy: Real-life Approaches to Combinations on Scientifically Speaking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-therapy-real-life-approaches-to-combinations-on-scientifically-speaking/19913/From serial PDT to novel combinations, specialists describe how they treat AKs in real-world settings. Scientifically Speaking host Joel L. Cohen, MD reviews cases from Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD.Radiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to AleviEBD Insights
https://practicaldermatology.com/conferences/maui-derm-2022/ebd-insights/20049/There are a number of new and reliable energy-based devices available. Michael H. Gold, MD discusses tried-and-true technologies as well as new and innovative devices that offer efficacious options on the market for a variety of dermatologic needs.Exploring High-Dose Neurotoxin Injections
https://practicaldermatology.com/conferences/maui-derm-2022/exploring-high-dose-neurotoxin-injections/20055/Michael H. Gold, MD shares his thoughts on the potential benefits of high-dose neurotoxin injections for some patients. He discusses his experience and the kind of results he's been able to achieve.EBDs and the Shape of Things to Come
https://practicaldermatology.com/conferences/asds-2021/ebds-and-the-shape-of-things-to-come/20019/Demand for procedures to tighten and tone continues to grow, and technology continues to evolve to meet patient demands. Michael H. Gold, MD discusses new and emerging energy-based devices that may improve outcomes and the patient experience.DermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using their